3月25日，中国中药（00570）发布2024年财报：营收165.1亿元，同比下滑8.9%；除税后溢利仅2077万元，较上年13.96亿元下跌98.5%。业绩下滑主要受中药配方颗粒集采降价、中药材成本高位运行及市场竞争加剧影响。剔除资产处置等特殊因素，调整后净利润6.36亿元，同比仍腰斩54.5%。核心业务中，中药饮片和中成药营收分别增长17.9%和14%，但中药配方颗粒收入下降23.5%。董事会...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.